GSK

Chasing Mylan, Hikma tries again with rejected generic Advair in US
Chasing Mylan, Hikma tries again with rejected generic Advair in US
Pharmaforum
Hikma
FDA
generics
GSK
Advair
asthma
COPD
Flag link:
AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron
AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron
Biopharma Dive
R&D
drug discovery
machine learning
artificial intelligence
GSK
Hal Barron
Flag link:
Top 10 pharma settlements since 2018
Top 10 pharma settlements since 2018
Fierce Pharma
settlements
Reckitt Benckiser
JNJ
Bayer
Allergan
Actelion
Purdue Pharma
Teva Pharmaceutical
Endo
Teikoku
Insys
Pfizer
GSK
Astellas
Amgen
Flag link:
GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is
GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is
Fierce Pharma
GSK
vaccines
drug shortages
Shingrix
shingles
Flag link:
Nucala works in rare inflammatory disease, says GSK
Nucala works in rare inflammatory disease, says GSK
PM Live
GSK
clinical trials
Nucala
hypereosinophilic syndromes
HES
Flag link:
GSK must continue to improve R&D, says CEO Walmsley
GSK must continue to improve R&D, says CEO Walmsley
Pharmaforum
GSK
R&D
Emma Walmsley
Pharma CEOs
Flag link:
Top execs from AstraZeneca, Roche, Sanofi and GSK tout China investments at import expo
Top execs from AstraZeneca, Roche, Sanofi and GSK tout China investments at import expo
Fierce Pharma
China
AstraZeneca
Roche
Sanofi
GSK
Flag link:
GlaxoSmithKline leans on respiratory franchise with Trelegy share-grab
GlaxoSmithKline leans on respiratory franchise with Trelegy share-grab
Fierce Pharma
GSK
Trelegy Ellipta
COPD
Flag link:
GSK lifts annual profit forecast after third quarter beat on vaccines strength
GSK lifts annual profit forecast after third quarter beat on vaccines strength
Yahoo/Reuters
GSK
earnings
Flag link:
GlaxoSmithKline's RIPK1 inhibitor dead on arrival
GlaxoSmithKline's RIPK1 inhibitor dead on arrival
Fierce Biotech
GSK
GSK095
pancreatic cancer
Flag link:
Pfizer, GSK, J&J and more strike $248M deal to exit long-running Medicaid fraud suit
Pfizer, GSK, J&J and more strike $248M deal to exit long-running Medicaid fraud suit
Fierce Pharma
Medicaid
settlement
GSK
JNJ
Pfizer
Flag link:
GSK’s TB vaccine makes a big step forward towards licensing
GSK’s TB vaccine makes a big step forward towards licensing
Pharmaforum
GSK
vaccines
tuberculosis
M72/AS01E
Flag link:
GlaxoSmithKline kick-starts first-of-its-kind late-stage antibiotic test
GlaxoSmithKline kick-starts first-of-its-kind late-stage antibiotic test
Fierce Biotech
GSK
antibiotics
antibiotic resistance
gepotidacin
Flag link:
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Endpoints
GSK
Zejula
ovarian cancer
FDA
PARP inhibitors
Flag link:
Bavarian Nordic to buy GSK’s rabies and tick-borne encephalitis vaccines
Bavarian Nordic to buy GSK’s rabies and tick-borne encephalitis vaccines
Pharmaceutical Business Review
Bavarian Nordic
GSK
vaccines
M&A
rabies
tick-borne encephalitis
Flag link:
GSK joins other drugmakers recalling Zantac products
GSK joins other drugmakers recalling Zantac products
Fierce Pharma
GSK
ranitidine
product recalls
OTC
Flag link:
GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors
GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors
Fierce Pharma
GSK
ViiV Healthcare
Dovato
DTC ads
HIV
Flag link:
GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma
GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma
Pharmaceutical Business Review
GSK
Innoviva
Trelegy Ellipta
asthma
Flag link:
GSK’s Walmsley backs #MeTooPay gender pay campaign
GSK’s Walmsley backs #MeTooPay gender pay campaign
Pharmaforum
GSK
Pharma CEOs
Emma Walmsley
gender gap
Flag link:
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Flag link:

Pages